Application Scope

Emitasvir is an NS5A inhibitor used in combination with Sofosbuvir for the treatment of chronic hepatitis C virus (HCV) infection in adults. It is effective against HCV genotypes 1 through 6, including those with compensated cirrhosis.

Characteristics

Ingredients: Emitasvir phosphate (the prodrug form of emitasvir)
Properties: Emitasvir is an orally active antiviral agent that inhibits the HCV NS5A protein, which is crucial for viral replication and assembly.
Packaging Specification: Typically available as film-coated tablets containing 0.1g
Storage: Store at room temperature, away from moisture and heat.
Expiry Date: Refer to the product packaging for the specific expiry date.
Executive Standard: Manufactured in accordance with Good Manufacturing Practices (GMP) and local regulatory standards.
Approval Number: Specific approval numbers vary by country; please consult local regulatory authorities.
Date of Revision: Refer to the product packaging for the date of the latest revision.
Manufacturer: Emitasvir is developed by Gilead Sciences, a biopharmaceutical company.

Guidelines for the Use of Emitasvir

Dosage and Administration:
- Recommended Dosage: 200 mg of emitasvir once daily, co-administered with 400 mg of sofosbuvir.
- Treatment Duration: Typically 12 weeks for treatment-naïve patients without cirrhosis or with compensated cirrhosis.
- Administration: Taken orally, with or without food.
Adverse Reactions:
- Common Side Effects: Headache, fatigue, nausea.
- Serious Adverse Events: Elevated liver enzymes, bradycardia (when co-administered with sofosbuvir), and hypersensitivity reactions.
Contraindications:
- Absolute Contraindications: Co-administration with strong inducers of P-glycoprotein (e.g., rifampin, St. John’s wort) is contraindicated.
- Relative Contraindications: Use during pregnancy and breastfeeding is not recommended; effective contraception should be used during treatment.
Precautions:
- Liver Function Monitoring: Regular monitoring of liver function tests is recommended during treatment.
- Drug Interactions: Be cautious when co-administering with other medications metabolized by cytochrome P450 enzymes.

Interactions

Drug Interactions:
Contraindicated Drugs: Strong P-glycoprotein inducers (e.g., rifampin, St. John’s wort).
Caution Advised: Other drugs metabolized by cytochrome P450 enzymes; consult with a healthcare provider before co-administering.

Note:

If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
It is only for internal discussion among medical staff and does not serve as a basis for medication. For specific medication guidelines, please consult the attending physician.